AQR Capital Management
PGNX

AQR Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

AQR Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,012
Closed -$133K – 2301
2017
Q3 		$133K Sell
18,012
-31,720
-64% -$201K ﹤0.01% 2212
2017
Q2 		$338K Hold
49,732
– – ﹤0.01% 2007
2017
Q1 		$469K Buy
+49,732
New +$496K ﹤0.01% 1908
2016
Q1 		– Sell
-28,144
Closed -$173K – 2319
2015
Q4 		$173K Sell
28,144
-55,733
-66% -$365K ﹤0.01% 2174
2015
Q3 		$480K Sell
83,877
-15,533
-16% -$119K ﹤0.01% 1734
2015
Q2 		$742K Buy
99,410
+36,510
+58% +$221K ﹤0.01% 1638
2015
Q1 		$376K Buy
62,900
+28,300
+82% +$178K ﹤0.01% 1796
2014
Q4 		$262K Buy
+34,600
New +$207K ﹤0.01% 2263
2014
Q3 		– Sell
-18,100
Closed -$78K – 2625
2014
Q2 		$78K Sell
18,100
-42,600
-70% -$163K ﹤0.01% 2482
2014
Q1 		$248K Buy
60,700
+3,200
+6% +$16.4K ﹤0.01% 2351
2013
Q4 		$306K Buy
+57,500
New +$253K ﹤0.01% 2289
2013
Q3 		– Sell
-250,000
Closed -$1.11M – 2562
2013
Q2 		$1.11M Buy
+250,000
New +$1.12M ﹤0.01% 1522

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

AQR Capital Management's PGNX Position: Q4 2017 in Review

AQR Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 18,012 shares — an estimated $133K sold.

AQR Capital Management first reported a position in PGNX in Q2 2013 and held it in 12 quarters. The position peaked at $1.11M in Q2 2013. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • AQR Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • AQR Capital Management sold 18,012 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $133K.
  • AQR Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
  • AQR Capital Management's Progenics Pharmaceuticals Inc position peaked at $1.11M in Q2 2013.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on AQR Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.